Butylated hydroxyanisole (
BHA; a mixture of 2- and 3-
BHA) is widely used as a potent
antioxidant, but is reported to have adverse effects, such as
carcinogenesis and pro-inflammatory activity, possibly due to the
pro-oxidant property of this compound.
2-Methoxyphenol dimers derived from
ferulic acid were recently demonstrated to inhibit the expression of
lipopolysaccharide-stimulated
cyclooxygenase-2 (COX-2) via redox-sensitive
transcription factors such as
nuclear factor kappa B or
activator protein-1 (AP-1), due to a weakening of its
pro-oxidant property by dimerization. To develop anti-inflammatory and/or anticancer drugs for the prevention of oral diseases, such as
leukoplakia and destructive
chronic periodontitis, whether
2-BHA (2-tert-butyl-4-methoxyphenol) and its synthetic ortho dimer, bis-
BHA (3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-diol) can inhibit
AP-1 transcriptional activity stimulated by Porphyromonas gingivalis fimbriae was examined. The fimbria-stimulated
AP-1 activation of RAW 264.7 murine macrophages was markedly inhibited by bis-
BHA. However,
BHA showed slight inhibition. Furthermore, bis-
BHA significantly inhibited fimbria-induced COX-2 gene expression, which is closely involved with
inflammation and
carcinogenesis. These findings suggest that bis-
BHA may possess a potent anti-inflammatory effect against oral diseases.